Loading
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Trastuzumab.
In plain words · FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer and HER2-positive breast cancer.
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG).
No product in this corpus aims at FCGR3A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FCGR3A: RNA tissue enhanced (lung 196 nTPM, lymphoid tissue 285 nTPM); blood lineage lineage enriched (monocytes 4,107 nTPM); high antibody staining in 4 normal tissues; highest cancer staining ovarian cancer (1 of 10 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas FCGR3A tissue; Open Targets ENSG00000203747 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Ravetch J.V. et al, J. Exp. Med, 1989, "Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions". Source.
Sources: HGNC HGNC:3619 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P08637 (protein name, function text, keywords and locations (REST API)); CIViC gene FCGR3A (2 evidence items, 0 assertions, 1 variants; diseases: Breast Cancer, HER2 Positive Breast Cancer (GraphQL API, CC0))
Receptor for the invariable Fc fragment of immunoglobulin gamma (IgG). Optimally activated upon binding of clustered antigen-IgG complexes displayed on cell surfaces, triggers lysis of antibody-coated cells, a process known as antibody-dependent cellular cytotoxicity (ADCC). Does not bind free monomeric IgG, thus avoiding inappropriate effector cell activation in the absence of antigenic trigger. Mediates IgG effector functions on natural killer (NK) cells. Binds antigen-IgG complexes generated upon infection and triggers NK cell-dependent cytokine production and degranulation to limit viral load and propagation. Involved in the generation of memory-like adaptive NK cells capable to produce high amounts of IFNG and to efficiently eliminate virus-infected cells via ADCC. Location: Cell membrane; Secreted (UniProt). Locus 1q23.3 (HGNC).
RNA: tissue enhanced (lung 196 nTPM, lymphoid tissue 285 nTPM), detected in all normal tissues. Blood: lineage enriched (monocytes 4,107 nTPM).
Medium: Bone marrow, Testis.
HPA FCGR3A tissue · HPA FCGR3A pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"FCGR3A" OR ABSTRACT:"FCGR3A" OR TITLE:"Fc gamma receptor IIIa" OR ABSTRACT:"Fc gamma receptor IIIa" OR TITLE:"Low affinity immunoglobulin gamma Fc region receptor III-A" OR ABSTRACT:"Low affinity immunoglobulin gamma Fc region receptor III-A" OR TITLE:"CD16" OR ABSTRACT:"CD16" OR TITLE:"CD16a" OR ABSTRACT:"CD16a" OR TITLE:"FcgammaRIIIa" OR ABSTRACT:"FcgammaRIIIa") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about FCGR3A, not a curated reading list.
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
Shares NK-cell recognition: missing self & stress ligands, HER2-positive breast cancer.
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.
Shares Complement in cancer, NK-cell recognition: missing self & stress ligands.